A Year After ‘Pivot To Growth’, Teva Keeps Pushing Forward With Innovative Assets
Firm Highlights LAI Olanzapine, As Trial Results Come Nine Months Ahead Of Schedule
• By David Wallace
Another of Teva’s innovative assets has delivered results • Source: Shutterstock 
